Mol Med Rep:Der p2‑A20 DNA疫苗能够减弱过敏性炎症

2019-11-08 AlexYang MedSci原创

过敏性鼻炎(AR)是一种常见的疾病,需要更加方便,安全和有效的抗原特异性免疫疗法。最近,有研究人员调查了鼻内注射能够共表达der p2和a20蛋白的真核表达载体对过敏性鼻炎小鼠的治疗效果。研究人员通过纳米粒子包装pVAX1-Der p2-A20疫苗,并通过建立了Balb/c过敏性鼻炎小鼠模型。之后评估了DNA疫苗对鼻过敏炎症的治疗效果,并通过ELISA确定了lgE,slgE和lgG以及细胞因子水平

过敏性鼻炎(AR)是一种常见的疾病,需要更加方便,安全和有效的抗原特异性免疫疗法。最近,有研究人员调查了鼻内注射能够共表达der p2和a20蛋白的真核表达载体对过敏性鼻炎小鼠的治疗效果。

研究人员通过纳米粒子包装pVAX1-Der p2-A20疫苗,并通过建立了Balb/c过敏性鼻炎小鼠模型。之后评估了DNA疫苗对鼻过敏炎症的治疗效果,并通过ELISA确定了lgE,slgE和lgG以及细胞因子水平。研究人员还利用流式细胞仪检测了脾脏中CD4+CD25+Foxp3+调控T细胞的比例。研究人员成功的构建了共表达Der p2和A20的DNA疫苗并包装进了PLGA纳米颗粒。研究发现,鼻内注射Der p2?A20 DNA疫苗能够显著的减弱Der p2诱导的鼻过敏炎症。血清Der p2特异性lgE,IL-4和IL-13的表达水平受到抑制,而在Der p2-a20 DNA疫苗治疗后,Der p2-特异性IgG1、IgG2a和IFN-γ表达水平在血清和脾CD4+CD 25+Foxp 3+ Treg细胞群中显著增加。

最后,研究人员指出,他们的结果表明了Der p2?A20 DNA疫苗能够减弱鼻过敏性炎症并促进脾Treg细胞群。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047182, encodeId=737e204e182d9, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Sep 09 11:42:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059204, encodeId=054f205920425, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 03 06:42:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423403, encodeId=157f142340337, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610108, encodeId=4de91610108cd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047182, encodeId=737e204e182d9, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Sep 09 11:42:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059204, encodeId=054f205920425, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 03 06:42:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423403, encodeId=157f142340337, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610108, encodeId=4de91610108cd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047182, encodeId=737e204e182d9, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Sep 09 11:42:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059204, encodeId=054f205920425, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 03 06:42:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423403, encodeId=157f142340337, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610108, encodeId=4de91610108cd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 mnda
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047182, encodeId=737e204e182d9, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Sep 09 11:42:00 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059204, encodeId=054f205920425, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Sep 03 06:42:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423403, encodeId=157f142340337, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610108, encodeId=4de91610108cd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 04:42:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]

相关资讯

Clin Cancer Res:新型抗肿瘤DNA疫苗问世,同时靶向7个位点!

目前世界各国研究人员均在进行肿瘤特异性抗原的筛选工作,这令免疫疗法成为众多肿瘤患者的救命药物。但随着各类研究的逐渐深入,研究者发现由于较低的CD8+T细胞免疫原性、载体毒性及有限的特异性靶抗原等因素使得 抗肿瘤疫苗的研发工作进展缓慢。

Clin Cancer Res:促进T细胞浸润肿瘤,DNA疫苗联合PD-1治疗HPV相关头颈癌可达到持续完全缓解

近期,来自宾夕法尼亚大学佩尔曼医学院的研究团队发现一种治疗用疫苗可以增强抗体和T细胞,帮助它们浸润到肿瘤中并抵抗人乳头瘤病毒(HPV)相关的头颈癌。该研究团队在两组晚期头颈部鳞状细胞癌(HNSCCa)患者中测试这种免疫治疗方法,发现86%的患者T细胞活性升高。

针对埃博拉病毒的DNA疫苗在临床前研究中显示出长期疗效

发表在《Journal of Infectious Diseases》上的临床前研究数据表明,一种新型合成DNA疫苗可以完全防止埃博拉病毒的感染。

DNA疫苗治疗晚期结直肠癌

近日,研究人员首次在人类中测试了DNA疫苗与抗体联用的方法来治疗晚期结直肠癌(CRC),结果表明这种双管齐下的方法有可能延长患者的预期寿命。在DNA疫苗与抗体联合使用方案中,该疫苗能够增强人体对肿瘤的免疫反应,免疫检查点阻断抗体能够阻断人体对DNA疫苗效力的天然防御,两者功能的有机结合为肿瘤的治疗提供了可能

新开发的DNA疫苗能够有效预防阿兹海默症的发生

最近一项研究成功地设计出了用于皮下注射的靶向阿兹海默症的DNA疫苗。该疫苗能够引发机体产生针对阿兹海默症毒性蛋白的特异性抗体。 这一由Peter O'Donnell Jr.脑研究所的科学家们做出的研究成果在动物水平证明了含有beta淀粉样蛋白的编码DNA的疫苗能够引发良好的免疫反应,而且该疫苗对于临床使用具有一定的安全性。 该研究的共

我国DNA疫苗获得批准

5月29日,根据国家农业农村部第30号公告,经批准,中国农业科学院哈尔滨兽医研究所研制的用于预防H5亚型禽流感的DNA疫苗,经过严格的审评程序,获得国家一类新兽药证书,这是我国获得批准的首个人和动物的DNA疫苗产品,也是哈兽研动物流感团队继成功研制出重组禽流感病毒灭活疫苗和禽流感-新城疫重组二联活疫苗后的又一项重大产业技术创新成果。DNA疫苗是将编码目的抗原蛋白基因序列的质粒经肌肉注射导入宿主细胞